DnB Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $236K | Sell |
10,919
-4,692
| -30% | -$101K | ﹤0.01% | 688 |
|
|
2025
Q1 | $259K | Buy |
15,611
+1,409
| +10% | +$23.4K | ﹤0.01% | 699 |
|
|
2024
Q4 | $261K | Buy |
14,202
+3,964
| +39% | +$72.7K | ﹤0.01% | 696 |
|
|
2024
Q3 | $157K | Buy |
10,238
+113
| +1% | +$1.74K | ﹤0.01% | 698 |
|
|
2024
Q2 | $165K | Buy |
+10,125
| New | +$165K | ﹤0.01% | 697 |
|
|
2023
Q3 | – | Sell |
-12,141
| Closed | -$291K | – | 659 |
|
|
2023
Q2 | $291K | Buy |
+12,141
| New | +$291K | ﹤0.01% | 650 |
|
|
2022
Q3 | – | Sell |
-46,171
| Closed | -$651K | – | 647 |
|
|
2022
Q2 | $651K | Sell |
46,171
-21,471
| -32% | -$303K | ﹤0.01% | 617 |
|
|
2022
Q1 | $1.64M | Sell |
67,642
-14,440
| -18% | -$350K | 0.01% | 570 |
|
|
2021
Q4 | $1.92M | Sell |
82,082
-8,758
| -10% | -$204K | 0.01% | 569 |
|
|
2021
Q3 | $1.51M | Sell |
90,840
-2,119
| -2% | -$35.2K | 0.01% | 575 |
|
|
2021
Q2 | $2.27M | Buy |
92,959
+483
| +0.5% | +$11.8K | 0.02% | 520 |
|
|
2021
Q1 | $2.39M | Buy |
92,476
+37,378
| +68% | +$964K | 0.02% | 500 |
|
|
2020
Q4 | $2.95M | Buy |
55,098
+32,556
| +144% | +$1.74M | 0.03% | 381 |
|
|
2020
Q3 | $930K | Buy |
+22,542
| New | +$930K | 0.01% | 531 |
|